Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $948,081 | $1,211,723 | $1,211,723 |
| - Cash | $489,711 | $230,440 | $4,158 |
| + Debt | $738 | $657 | $0 |
| Enterprise Value | $459,108 | $981,940 | $1,207,565 |
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| EBITDA | -$82,333 | -$39,870 | -$37,722 |
| % Margin | – | – | – |
| Net Income | -$67,995 | -$51,985 | -$37,845 |
| % Margin | – | – | – |
| EPS Diluted | -1.25 | -1 | -0.73 |
| % Growth | -25% | -37% | – |
| Operating Cash Flow | -$74,751 | -$45,628 | -$32,076 |
| Capital Expenditures | -$71 | -$586 | -$192 |
| Free Cash Flow | -$74,822 | -$46,214 | -$32,268 |